axsomelogo-468x57.jpg
Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 08, 2020 07:00 ET | Axsome Therapeutics, Inc.
Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further deepen innovative...
axsomelogo-468x57.jpg
Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate
January 13, 2020 06:00 ET | Axsome Therapeutics, Inc.
Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy Expands Axsome’s pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia ...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in CONCERT Phase 2 Trial in Narcolepsy
December 03, 2019 06:00 ET | Axsome Therapeutics, Inc.
Demonstrated statistically significant reduction in cataplexy attacks compared to placebo (p<0.001 on primary endpoint) Reduced excessive daytime sleepiness compared to placebo (p=0.003 on ESS;...
axsomelogo-468x57.jpg
Axsome Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
November 07, 2019 07:00 ET | Axsome Therapeutics, Inc.
GEMINI Phase 3 placebo-controlled trial of AXS-05 in MDD completed enrollment and on track for readout of topline results by year-end 2019 STRIDE-1 Phase 3 trial of AXS-05 in TRD to conclude patient...
gmi 2018.png
Sleep Tech Devices Market value to cross $27 billion by 2025: Global Market Insights, Inc.
November 05, 2019 05:00 ET | Global Market Insights, Inc
Selbyville, Delaware, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Global Sleep Tech Devices Market is projected to surpass USD 27 billion by 2025, according to a new research report by Global Market...
axsomelogo-468x57.jpg
Axsome Therapeutics Completes Patient Enrollment in the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy
October 21, 2019 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
axsomelogo-468x57.jpg
Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy
January 30, 2019 07:00 ET | Axsome Therapeutics, Inc.
Topline results anticipated in 2Q 2019 NEW YORK, Jan. 30, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies...
axsomelogo-468x57.jpg
Axsome Therapeutics Receives FDA Orphan Drug Designation for AXS-12 for the Treatment of Narcolepsy
October 17, 2018 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
axsomelogo-468x57.jpg
Axsome Therapeutics to Host Call Today with Key Opinion Leader Focusing on AXS-12 and Unmet Needs in Narcolepsy
October 16, 2018 07:05 ET | Axsome Therapeutics, Inc.
Conference call and webcast to be held today at 8:00 AM Eastern Time NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces AXS-12 for the Treatment of Narcolepsy
October 16, 2018 07:00 ET | Axsome Therapeutics, Inc.
Narcolepsy is a debilitating, orphan neurological condition with limited treatment options Phase 2 trial set to start in 4Q 2018 with results anticipated in 1H 2019 Conference call and webcast...